Edition:
United States

Moderna Says Merck Has Elected To Conduct A Phase 1 Clinical Trial For mRNA-1172


Wednesday, 8 May 2019 10:35am EDT 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MODERNA INC - MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.